Press Releases

16 May 2021

Xbrane announces ambition to generate positive operating cash flow monthly by late 2023/early 2024 and to initiate one new biosimilar development program per annum.

11 May 2021

Xbrane is hosting a Virtual Capital Markets Day on May 17th, 2021

06 May 2021

Announcement from Xbrane Biopharma’s annual general meeting

06 May 2021

Xbrane Biopharma releases interim report for January – March 2021

04 May 2021

Invitation to presentation of Xbrane Biopharma’s interim report January – March, 2021 on May 6, 2021.

15 Apr 2021

Xbrane Biopharma expands in-house Biosimilar development capabilities with new Biotech lab and invites participants to Virtual Capital Markets day on May 17.

31 Mar 2021

Xbrane Biopharma releases Annual report for 2020

30 Mar 2021

Notice of annual general meeting in Xbrane Biopharma AB

15 Mar 2021

Xbrane strengthens the organization with the appointment of Erik Domines as General Counsel

26 Feb 2021

Xbrane Biopharma releases Year-end report 2020

24 Feb 2021

Invitation to presentation of Xbrane Biopharma’s year-end report, 2020.

24 Feb 2021

To further focus on becoming a world leading biosimilar developer Xbrane enters a non-binding term-sheet to divest its Italian subsidiary Primm Pharma

23 Feb 2021

Meet Xbrane at Börsveckans Digitala Småbolagsdag

11 Jan 2021

Xbrane appoints Anette Lindqvist as new Chief Financial Officer & Head of Investor Relations

05 Jan 2021

Xbrane re-negotiates pre-existing IP license agreement with Vaxiion Therapeutics